Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Journal of Clinical Oncology · 20.06.2025 · 43 (18) · 2107-2118
DOI: 10.1200/jco.23.01965 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2025. Verfasst von Inna M Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Antibodies, Monoclonal, Humanized, Cachexia. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
PURPOSE This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557 ) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti–interleukin-6 (IL-6) receptor antibody tocilizumab (Toc) for advanced pancreatic cancer (PC). METHODS A safety cohort received Gem 1,000 mg/m 2 and Nab 125 mg/m 2 on days 1, 8, and 15, and Toc 8 mg/kg on day 1 for each 28-day cycle. Participants with modified Glasgow prognostic scores of 1 or 2 were randomly assigned 1:1 to receive Gem/Nab/Toc or Gem/Nab. The primary end point was the overall survival (OS) rate at 6 months (OS6). Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. Exploratory end points were cachexia, quality of life, and biomarkers, including the cachexia-promoting protein, growth differentiation factor 15 (GDF15). RESULTS Overall, 147 patients were treated, including six safety cohort participants. The median follow-up period was 8.1 months (IQR, 4.2-13.9). OS6 was 68.6% (95% CI, 56.3 to 78.1) for the Gem/Nab/Toc group and 62.0% (49.6-72.1) for the Gem/Nab group ( P = .409). OS for Gem/Nab/Toc versus Gem/Nab improved at 18 months (27.1% v 7.0%, P = .001). No differences in median OS, PFS, or ORR were observed. Incidence of grade-3+ treatment-related adverse events (TrAEs) was 88.1% for Gem/Nab/Toc and 63.4% for Gem/Nab ( P < .001). Gem/Nab/Toc decreased muscle loss versus Gem/Nab, with median change +0.1013% versus –3.430% ( P = .0012) at 2 months and +0.7044 versus –3.353% ( P = .036) at 4 months. Incidence of muscle loss was 43.48% on Gem/Nab/Toc versus 73.52% on Gem/Nab at 2 months ( P = .0045) and 41.82% versus 68.75% ( P = .0062) at 4 months. GDF15 was not changed by Gem/Nab or Gem/Nab/Toc. CONCLUSION Although the primary end point was not met and TrAEs were increased by Toc, increased survival at 18 months and reduced muscle wasting support an anticachexia effect of IL-6 blockade independent of GDF15. Further studies could leverage these findings for precision anticachexia therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Medicine, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.
- Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.
- Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Inna M Chen, Libbie M Silverman, Katherine R Pelz, Kasper Madsen, Kevin Z M Lim, Omnia Gaafer, Anna C Ferreira, Michael C Ostrowski, Dorte Nielsen
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Chen, I. M., Johansen, J. S., Theile, S., Silverman, L. M., Pelz, K. R., Madsen, K., Dajani, O., Lim, K. Z. M., Lorentzen, T., Gaafer, O., Koniaris, L. G., Ferreira, A. C., Neelon, B., Guttridge, D. C., Ostrowski, M. C., Zimmers, T. A., & Nielsen, D. (2025). Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. Journal of Clinical Oncology, 43(18), 2107-2118. https://doi.org/10.1200/jco.23.01965
Vancouver
Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, et al. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. Journal of Clinical Oncology. 2025;43(18):2107-2118. doi:10.1200/jco.23.01965
BibTeX
@article{Chen2025,
author = {Chen, Inna M and Johansen, Julia S and Theile, Susann and Silverman, Libbie M and Pelz, Katherine R and Madsen, Kasper and Dajani, Olav and Lim, Kevin Z M and Lorentzen, Torben and Gaafer, Omnia and Koniaris, Leonidas G and Ferreira, Anna C and Neelon, Brian and Guttridge, Denis C and Ostrowski, Michael C and Zimmers, Teresa A and Nielsen, Dorte},
title = {Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {18},
pages = {2107--2118},
doi = {10.1200/jco.23.01965}
}
EUVIMED